CAM
FULC icon

Cormorant Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Cormorant Asset Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,081,490
Closed -$3.08M – 70
2023
Q1 		$3.08M Buy
+1,081,490
New +$9.69M 0.2% 55

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cormorant Asset Management's FULC Position: Q2 2023 in Review

Cormorant Asset Management sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 1,081,490 shares — an estimated $3.08M sold.

Cormorant Asset Management first reported a position in FULC in Q1 2023 and held it in 1 quarter. The position peaked at $3.08M in Q1 2023. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

  • Cormorant Asset Management reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 1,081,490 Fulcrum Therapeutics shares in Q2 2023, an estimated $3.08M.
  • Cormorant Asset Management first reported a position in Fulcrum Therapeutics in Q1 2023 and held it in 1 quarter.
  • Cormorant Asset Management's Fulcrum Therapeutics position peaked at $3.08M in Q1 2023.
  • 88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.